Covid-19 Innovation Challenges by Innoget

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Innovative Products and Technologies · United Kingdom

Summary of the technology

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors
of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules
are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion
envelopes, creating a physical barrier to viral envelope and cell membrane fusion.

These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against
herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can
potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Covid-19 Innovation Challenges by Innoget

Advantages

Since the viral envelope is highly conserved these fusion inhibitors may offer considerable advantages over traditional antiviral interventions. By specifically targeting the viral envelope (not viral protein) the risk of selecting for resistance will likely be reduced. Furthermore, the highly conserved lipid bilayer shared among most enveloped viruses may allow these fusion inhibitors to act against a wide range of enveloped viruses (including both DNA & RNA enveloped viruses).

• Low concentrations of amphipathic nucleoside derivatives can inhibit the infectivity of mature virions.
• These molecules can inhibit the infectivity of virions with a safety index greater than 1,000 and without any major cytotoxic or cytostatic effects.
• Animal studies indicated that these molecules can neutralize and prevent the sexual transmission of HSV-2.
• In vitro data illustrated that these nucleoside derivatives can inhibit the infectivity for a range of RNA & DNA enveloped viruses including: HSV1,2, vesicular stomatitis and Sindbis
• Testing underway against COVID-19

Intellectual property status

Granted Patent
Patent number: US8633308
Where: United States

Granted Patent
Patent number: CA2679257
Where: Canada

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Additional information (attached documents)

Related keywords

  • Pharmaceutics
  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Medical Technology / Biomedical Engineering
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Human vaccines
  • Emergency Medicine Technology
  • Biology / Biotechnology
  • Micro- and Nanotechnology related to Biological sciences
  • Medical Health related
  • Therapeutic
  • Other Medical/Health Related
  • Pharmaceuticals/fine chemicals
  • Other medical/health related (not elsewhere classified)
  • Welfare technologies
  • antiviral
  • coronavirus
  • sars
  • covid19

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.